Results 211 to 220 of about 74,509 (297)

Pharmacogenetic and Pharmacogenomic Studies [PDF]

, 2003
François Alhenc‐Gelas, Laurent Parmentier, Anne Bisagni, P.Y. Arnoux, E. Baumelou, Philippe Beaune, Jean Boissel, F. Cambien, M. Cano-Petit, Jean-Pierre Deleuze, B. Diquet, Jacques Élion, L. Fluckiger, Christian Funck‐Brentano, Janos Job, P Lechat, Léo Mignot, Stéphane Mouly, A. Parent de Curzon   +18 more
openalex   +1 more source

Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes [PDF]

, 2019
Bloom, Adam Joseph, Kharasch, Evan D, Wang, Pan-Fen   +2 more
core   +2 more sources

Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1

Diabetes, Obesity and Metabolism, Volume 27, Issue 9, Page 5064-5071, September 2025.
Abstract Aims The objective was to assess weight reduction at Weeks 24 and 72 in participants treated with tirzepatide based on weight reduction response after 12 weeks of treatment in the SURMOUNT‐1 trial. Materials and Methods This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and ...
Jamy Ard, Clare J. Lee, Kimberly Gudzune, Brandi Addison, Ildiko Lingvay, Dachuang Cao, Casey J. Mast, Adam Stefanski, Beverly Falcon, Donna Mojdami   +9 more
wiley   +1 more source

Cataloging Actionable Pharmacogenomic Variants for Indian Clinical Practice: A Scoping Review. [PDF]

J Xenobiot
Kulkarni SS, R V, Das A, Iyer GR.
europepmc   +1 more source

Posters: Pharmacogenomics and Proteomics in the Pharma Industry

, 2002

openalex   +1 more source

The reality of pharmacogenomics: optimizing therapeutic decision making. [PDF]

, 2003
Craig R. Lee, Darryl C. Zeldin
openalex   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions

European Journal of Haematology, Volume 115, Issue 3, Page 218-231, September 2025.
ABSTRACT Chronic myeloid leukemia (CML) has undergone a transformation from a fatal disease to a chronic, manageable condition with the advent of tyrosine kinase inhibitors (TKIs), particularly imatinib. This shift has significantly improved survival rates, and for some patients, achieving deep molecular response (DMR) has made treatment‐free remission
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Nicola Amodio, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Fortunato Morabito, Massimo Gentile   +9 more
wiley   +1 more source

How equipped are pharmacists for pharmacogenomics?: A cross-sectional study on knowledge, attitudes, and implementation practices in Saudi Arabia. [PDF]

Medicine (Baltimore)
Alharthi MS.
europepmc   +1 more source

Sequence and function in pharmacogenomics [PDF]

, 2003
Júlio Licinio, Ma‐Li Wong
openalex   +1 more source

Pharmacogenomics in Japan [PDF]

The Pharmacogenomics Journal, 2004
Kiichiro Tsutani, Hiroshi Gushima, Mieko Tamaoki   +2 more
openaire   +3 more sources